Evidence map›Paper›PMID 41939847›Full record

ReviewFrontiers in pharmacology2026

From multi-target mechanisms to clinical translation: the analgesic potential of quercetin.

Fuquan Wang, Yang Yang, Wen Wang, Bifa Fan

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fuquan WangDepartment of Pain Medicine, China-Japan Friendship Hospital, Beijing, China.
Yang YangDepartment of Pain Medicine, China-Japan Friendship Hospital, Beijing, China.
Wen WangDepartment of Pain Medicine, China-Japan Friendship Hospital, Beijing, China.
Bifa FanDepartment of Pain Medicine, China-Japan Friendship Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a major global health challenge, pain often eludes optimal management by current therapies due to limitations like side effects and inadequate efficacy in certain subtypes. Quercetin, a natural flavonoid, has emerged as a promising broad-spectrum analgesic, demonstrating efficacy in diverse pain models including inflammatory, neuropathic, and cancer-related pain. This review systematically delineates the broad-spectrum analgesic efficacy of quercetin across diverse pain conditions, including inflammatory, neuropathic, cancer, and postoperative pain. We comprehensively dissect its sophisticated molecular mechanisms, encompassing the suppression of neuroinflammation via modulating glial cell activation and polarization, the mitigation of oxidative stress and ferroptosis, the regulation of key ion channels and neuroreceptors, and the restoration of neural pathway homeostasis. Furthermore, we discuss innovative drug delivery strategies designed to overcome quercetin's pharmacokinetic limitations and enhance its therapeutic potential. Despite promising preclinical results, challenges in clinical translation, particularly regarding bioavailability and the need for robust clinical validation, are critically examined. By integrating the latest preclinical and clinical evidence and providing a pain-centric, mechanism-driven analytical framework, this review addresses the critical gap in dedicated research on quercetin's analgesic properties and offers a novel theoretical basis for the rational development of quercetin-based therapeutic strategies for clinical pain management. This study consolidates evidence on quercetin's analgesic pharmacology and translational potential, concluding that it represents a viable multi-target candidate, with future research poised to optimize its formulations and validate clinical efficacy for pain management.

Indexed as

analgesiamulti-target therapyneuroinflammationneuropathic painquercetin

Identifiers

PMID41939847
PMCPMC13044585

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.